Aigen Investment Management LP Purchases Shares of 6,335 CRISPR Therapeutics AG (NASDAQ:CRSP)

Aigen Investment Management LP acquired a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,335 shares of the company’s stock, valued at approximately $298,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Global Trust Asset Management LLC increased its holdings in CRISPR Therapeutics by 150.0% during the 2nd quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock worth $27,000 after purchasing an additional 300 shares in the last quarter. Larson Financial Group LLC grew its holdings in shares of CRISPR Therapeutics by 95.5% during the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after buying an additional 276 shares in the last quarter. GPS Wealth Strategies Group LLC raised its position in CRISPR Therapeutics by 99.7% in the 2nd quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock valued at $33,000 after buying an additional 307 shares during the last quarter. Itau Unibanco Holding S.A. bought a new stake in CRISPR Therapeutics in the 2nd quarter valued at approximately $35,000. Finally, Denver PWM LLC acquired a new position in CRISPR Therapeutics during the 2nd quarter worth approximately $45,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. Chardan Capital cut their price objective on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Barclays decreased their price target on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 6th. Truist Financial dropped their price objective on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday, August 8th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $53.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $74.94.

CRISPR Therapeutics Stock Up 0.9 %

Shares of NASDAQ:CRSP opened at $47.25 on Friday. CRISPR Therapeutics AG has a 12-month low of $43.42 and a 12-month high of $91.10. The company’s 50 day moving average price is $47.88 and its two-hundred day moving average price is $52.04. The firm has a market cap of $4.03 billion, a PE ratio of -16.70 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. The business had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same quarter in the prior year, the business posted ($1.41) earnings per share. On average, research analysts expect that CRISPR Therapeutics AG will post -5.2 EPS for the current year.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,089 shares of the company’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the sale, the general counsel now directly owns 62,597 shares in the company, valued at $2,896,989.16. This represents a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Samarth Kulkarni sold 30,000 shares of the business’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $55.62, for a total value of $1,668,600.00. Following the transaction, the chief executive officer now directly owns 196,540 shares of the company’s stock, valued at $10,931,554.80. This trade represents a 13.24 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 35,382 shares of company stock valued at $1,917,679. 4.10% of the stock is owned by corporate insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.